English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA framework based on advanced AI techniques can solve complex, computationally intensive problems faster and in a more more scalable way than state-of-the-art methods, according to a study led by engineers at the University of California San Diego. In the paper, which was published May 30 in Nature Machine Intelligence, researchers present HypOp, a framework that uses unsupervised learning and hypergraph neural networks.
Tag: Drug Discovery
Groundbreaking LLNL and BridgeBio Oncology Therapeutics collaboration announces start of human trials for supercomputing-discovered cancer drug
In a substantial milestone for supercomputing-aided drug design, Lawrence Livermore National Laboratory (LLNL) and BridgeBio Oncology Therapeutics (BridgeBio) today announced clinical trials have begun for a first-in-class medication that targets specific genetic mutations implicated in many types of cancer.
Innovative Techniques Open New Avenues in Drug Discovery for Brain Diseases
Volume 29, Issue 2 of SLAS Discovery features two review articles, six original research articles covering phenotypic screening perspectives, medulloblastoma therapies and interventions for neurodegenerative diseases.
Researchers Wrestle with Accuracy of AI Technology Used to Create New Drug Candidates
Researchers at the UNC School of Medicine, UCSF, Stanford, and Harvard determined that a protein prediction technology can yield accurate results in the hunt to efficiently find the best possible drug candidates for many conditions.
MD Anderson Research Highlights for May 8, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
GUIDE team develops computational approach to redesign antibodies for broader effectiveness against viral pandemics
In a groundbreaking development for addressing future viral pandemics, a multi-institutional team involving Lawrence Livermore National Laboratory researchers has successfully combined an artificial intelligence-backed platform with supercomputing to redesign and restore the effectiveness of antibodies whose ability to fight viruses has been compromised by viral evolution. The work was published in the journal Nature.
Simulated Chemistry: New AI Platform Designs Tomorrow’s Cancer Drugs
Researchers from University of California San Diego have developed a new AI tool to that generate new drug candidates for cancer, which could help streamline the typically laborious drug discovery process.
How Scientists Are Accelerating Chemistry Discoveries With Automation
Researchers have developed an automated workflow that could accelerate the discovery of new pharmaceutical drugs and other useful products. The new approach could enable real-time reaction analysis and identify new chemical-reaction products much faster than current laboratory methods.
Mimicking exercise with a pill
Could a pill replicate the benefits of exercise? Researchers have identified new compounds that seem to mimic some benefits of exercise in rodent cells. This discovery could help treat those with muscle wasting and other conditions. The scientists will present their results at ACS Spring 2024.
ReadCube Expands Its Award-Winning Literature Management Platform with the Launch of Literature Review
Digital Science is pleased to announce that ReadCube, an award-winning leader in literature management and full-text document delivery, has launched a new solution for research-driven organizations – known simply as Literature Review by ReadCube.
ReadCube Expands Its Award-Winning Literature Management Platform with the Launch of Literature Review
Digital Science is pleased to announce that ReadCube, an award-winning leader in literature management and full-text document delivery, has launched a new solution for research-driven organizations – known simply as Literature Review by ReadCube.
Device ‘smells’ seawater to discover, detect novel molecules
Researchers in ACS Central Science report a proof-of-concept device that “sniffs” seawater, trapping dissolved compounds for analyses. The team showed that the system could easily concentrate molecules that are present in underwater caves and holds promise for drug discovery in fragile ecosystems, including coral reefs.
Scientists build on artificial intelligence to create next-generation gastric acid treatment
Nagoya University researchers used AI to design and synthesize a new, highly effective gastric acid inhibitor, demonstrating the potential of AI in pharmaceutical development.
Broad-spectrum antiviral candidate targets dengue and SARS-CoV-2
A broad-spectrum antiviral drug candidate, 2-thiouridine, that targets positive-strand RNA viruses has been identified and characterized.
Icahn School of Medicine at Mount Sinai and the University of California San Diego Receive $8.5 Million Award to Establish a Data Integration Hub for NIH Common Fund Supported Programs
Researchers at the Icahn School of Medicine at Mount Sinai and the University of California San Diego have been awarded an $8.5 million grant to create a data integration hub aimed at accelerating novel therapeutics and cures for diseases within initiatives supported by the National Institutes of Health (NIH) Common Fund.
Emerging Drug Discovery Ecosystems in Virginia
A Special Issue of SLAS Discovery, Emerging Drug Discovery Ecosystems, is now available.
Mount Sinai Scientists Unlock Secrets of Red Blood Cell Transporter, Potentially Paving the Way for New Drugs
Researchers at the Icahn School of Medicine at Mount Sinai have identified the structure of a special transporter found in red blood cells and how it interacts with drugs.
Looking at the Latest in Life Sciences Discovery and Technology
The August 2023 issue of SLAS Technology, the open access journal emphasizing scientific and technical advances across the life sciences, is now available.
New Advancements in Assay Development Research
The July 2023 issue of SLAS Discovery, the open access journal focused on research progressing drug discovery, is now available.
AI brings hope for patients with lyosomal storage disease
Artificial intelligence is becoming increasingly important in drug discovery.
$11.7M from Department of Defense to fund research on common complication to traumatic brain injury
Researchers at the School of Science at IUPUI will lead grants to fund research toward an effective drug treatment for hydrocephalus, a condition commonly associated with complications from traumatic brain injury.
Announcing the SLAS Technology Editor’s Top 10 for 2023
The SLAS Technology Editor’s Top 10 for 2023 highlights technologies that address a broad range of unmet needs in both the laboratory and the clinic.
Using AI to create better, more potent medicines
While it can take years for the pharmaceutical industry to create medicines capable of treating or curing human disease, a new study suggests that using generative artificial intelligence could vastly accelerate the drug-development process.
UC San Diego First to Test Cancer Drugs in Space Using Private Astronaut Mission
The latest space experiments from UC San Diego and Axiom Space will explore therapies for breast and colorectal cancer aboard the ISS, and monitor astronauts’ stem cell health over time.
Analyzing CAR-T Cells with Image Cytometry for Potential Solid Tumor Treatments
The April 2023 issue of SLAS Discovery contains six full-length articles and one mini-review covering high-throughput screening (HTS) for protease-inhibiting drugs, high-content phenotypic screening and other life sciences research.
Dana-Farber Cancer Institute receives $10 million gift from the Linde Family Foundation
The Linde Family Foundation has made a $10 million gift to launch the Center for Therapeutic Discovery at Dana-Farber Cancer Institute. This new center will be home to a new team devoted to the development of novel therapeutics for patients with rare and hard-to-treat cancers.
Fiery response: “Siglec-14” receptors on human macrophages detect carbon nanotubes and provoke inflammation, finds study
Carbon nanotubes (CNTs) have become a mainstay of the field of nanotechnology.
SLAS Discovery Highlights Protocols in Drug Discovery for March Special Issue
The March special issue of SLAS Discovery deviates from its traditional focus on assay technology, disease area or molecular target to introduce and explore protocol articles – the newly accepted article type for outlining detailed scientific methods and procedures.
Sanford Burnham Prebys researchers awarded $2.6M to discover pancreatic cancer drugs
Cosimo Commisso, Ph.D., and Susanne Heynen-Genel, Ph.D., have received a grant from the National Cancer Institute (NCI) to advance a new treatment approach for pancreatic cancer.
UC San Diego’s Astrobiotechnology Hub to Drive Drug Discovery in Space
UC San Diego’s new Astrobiotechnology Hub brings together leaders in academia, biotechnology and aerospace industries under a united mission to advance stem cell science and commercialization in space.
St. Jude approach prevents drug resistance and toxicity
Scientists at St. Jude Children’s Research Hospital showed an effective method to avoid activating a major cellular detoxification receptor to overcome drug resistance and toxicity.
First-of-its-kind instrument officially ushers in new era of X-ray science
Arizona State University has officially begun a new chapter in X-ray science with a newly commissioned, first-of-its-kind instrument that will help scientists see deeper into matter and living things. The device, called the compact X-ray light source (CXLS), marked a major milestone in its operations as ASU scientists generated its first X-rays on the night of Feb. 2.
Laboratory Automation and Life Sciences Research Conference Open to Media Registration: February 26-March 1, 2023 in San Diego
The Society for Laboratory Automation and Screening (SLAS) invites members of the press, science journalists and trade press to attend the SLAS2023 International Conference and Exhibition, the society’s annual flagship conference.
Artificial Intelligence Aids Discovery of Super Tight-Binding Antibodies
UC San Diego scientists developed an artificial intelligence tool that could accelerate the development of new high affinity antibody drugs.
A New Assay Screening Method Shows Therapeutic Promise for Treating Auto-Immune Disease
The January 2023 issue of SLAS Discovery contains a collection of four full-length articles and one technical brief covering cancer research, high-throughput screening (HTS) assay development and other drug discovery exploration.
UC Irvine, UCLA researchers identify new therapeutic approach to prevent ARDS
A novel peptide designed by University of California, Irvine researchers has been found to suppress the damaging lung inflammation seen in acute respiratory distress syndrome, or ARDS. Their study, which appears in iScience, describes the first specific treatment designed to prevent the deadly disease, which can appear in patients with severe lung injury from infections with bacteria and viruses, like pneumonia, flu, respiratory syncytial virus (RSV) and COVID-19.
New Look at an Ancient Disease: Study Finds Novel Treatment Targets for Gout
UC San Diego scientists identify a new molecular model and potential therapeutic target for gout, the most common form of inflammatory arthritis.
Sanford Burnham Prebys announces start of Phase 2 clinical trial of DS-1211 in individuals with PseudoXanthoma Elasticum
A Phase 2 clinical trial has started of DS-1211 in individuals with Pseudoxanthoma Elasticum (PXE), a rare multisystem genetic disease that causes calcium deposits in soft tissue resulting in considerable morbidity. DS-1211 is a potential first-in-class small molecule developed through a research collaboration between Daiichi Sankyo and Sanford Burnham Prebys.
Sanford Burnham Prebys selected for participation in National Cancer Institute Chemical Biology Consortium
For the third time, Sanford Burnham Prebys has been selected by the Frederick National Laboratory for Cancer Research, currently operated by Leidos Biomedical Research, Inc., supporting the NCI Experimental Therapeutics (NExT) Program as a Center for the Chemical Biology Consortium (CBC).
Two drugs reverse key pancreatic cancer step in the lab
Two drugs — one brand new — reverse pancreatic cell changes that presage one of the hardest cancers to treat. Tested in cells, the drugs would be a promising early cancer treatment if they work in clinical trials.
New oneAPI Center of Excellence to Bring High-performance Simulations to Amber
New center will focus on enabling high-performance molecular dynamics simulations via oneAPI—an open, standards-based, cross-architecture programming model for CPUs and accelerators for faster application performance, more productivity and greater innovation.
The September Issue of SLAS Discovery Highlights a Label-Free SERS Method in Detecting SARS-CoV-2 and More
The September issue of SLAS Discovery is now available open access on ScienceDirect.
Developing antivirals for pandemic-level viruses
Researchers at the University of Illinois Chicago are working with the National Institutes of Health and University of Minnesota to establish a center for antiviral drug development for pandemic-level viruses, including Ebola and SARS-CoV-2.
Gilson’s VERITY® 1741 UV-VIS Detector is Specially Designed to Secure Semi-Preparative and Preparative HPLC Applications
Today, Gilson announced a new UV-VIS detector to its VERITY® line of purification systems. The VERITY® 1741 UV-VIS Detector is specifically designed with the needs of semi-preparative and preparative HPLC customers in mind.
Texas Biomed tapped for national ‘Dream Team’ developing antivirals against COVID-19 and other threats
Texas Biomedical Research Institute Professor Luis Martinez-Sobrido, PhD, an expert in virology, vaccines and antiviral research, has been recruited to collaborate with three of the nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern announced by NIH this spring.
SLAS Discovery July Issue Features a New Method of Detecting Metal Impurities in High-Throughput Screening – Available Now
The July issue of SLAS Discovery is now available Open Access on ScienceDirect.
Unexpected link between most common cancer drivers may yield more effective drugs
Two of the most common genetic changes that cause cells to become cancerous, which were previously thought to be separate and regulated by different cellular signals, are working in concert, according to new research from the University of Wisconsin–Madison. To date, researchers have focused on finding drugs that block one or the other to treat cancer.
MD Anderson Research Highlights for June 1, 2022
Current advances include new biomarkers to predict chimeric antigen receptor (CAR) T cell therapy outcomes and neurotoxicities, novel treatment targets for pre-cancerous pancreatic lesions and T-cell acute lymphoblastic leukemia, a new approach to improve immunotherapy responses in cold tumors, a profile of synthetic lethal targets for cancers with tumor suppressor loss, and promising clinical data for acute myeloid leukemia and cancers of unknown primary.
Mount Sinai Microbiome Lab Joins NIH’s Accelerating Medicines Partnership
The National Institutes of the Health (NIH) has awarded researchers at the Icahn School of Medicine at Mount Sinai a four-year grant to study the role of the human microbiome in rheumatoid arthritis, systemic lupus, and other autoimmune diseases. The grant is part of the NIH’s Accelerating Medicines Partnership® Autoimmune and Immune-Mediated Diseases (AMP® AIM) program, which is designed to speed the discovery of new treatments and diagnostics. It will support the Microbiome Technology and Analytic Center Hub (Micro-TEACH), a multidisciplinary team of researchers at Icahn Mount Sinai and NYU Langone Health.
COVID-19, MIS-C and Kawasaki Disease Share Same Immune Response
COVID-19, MIS-C and KD all share a similar underlying mechanism involving the over-activation of particular inflammatory pathways, UC San Diego study shows. Findings support novel drug targets for MIS-C.